Myelodysplastic Syndrome Updated.
Hasserjian RP.
Pathobiology. 2019;86(1):7-13. doi: 10.1159/000489702. Epub 2018 Jul 24.
Childhood Myelodysplastic Syndrome.
Chisholm KM, Bohling SD.
Clin Lab Med. 2023 Dec;43(4):639-655. doi: 10.1016/j.cll.2023.06.005. Epub 2023 Aug 7.
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
Battaglia MR, Cannova J, Madero-Marroquin R, Patel AA.
Curr Treat Options Oncol. 2024 Jun;25(6):752-768. doi: 10.1007/s11864-024-01217-0. Epub 2024 May 30.
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM, Lasho TL.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):450-459. doi: 10.1182/hematology.2020000130.
MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
Baidurin S, Akhmetzhanova S, Ilmalieva A, Sagyndykova G, Orazbekova A.
Georgian Med News. 2023 Jan;(334):103-107.
[Myelodysplastic syndrome : prognostic factors].
Gyan E, Thépot S.
Bull Cancer. 2023 Nov;110(11):1141-1146. doi: 10.1016/j.bulcan.2023.06.008. Epub 2023 Aug 1.
EnvIRONmental Aspects in Myelodysplastic Syndrome.
Petzer V, Theurl I, Weiss G, Wolf D.
Int J Mol Sci. 2021 May 14;22(10):5202. doi: 10.3390/ijms22105202.
Therapy-related myelodysplastic syndrome.
Candelaria M, Dueñas-Gonzalez A.
Expert Opin Drug Saf. 2015 May;14(5):655-65. doi: 10.1517/14740338.2015.1014340. Epub 2015 Feb 12.
Myelodysplastic syndrome.
Nakao S, Deeg HJ, Ishikawa T, Marsh J, List A, Tomonaga M.
Int J Hematol. 2005 Dec;82(5):412-6. doi: 10.1532/IJH97.05139.
Myelodysplastic syndrome.
Legare RD, Gilliland DG.
Curr Opin Hematol. 1995 Jul;2(4):283-92. doi: 10.1097/00062752-199502040-00008.
